Ionis Pharmaceuticals, Inc.
Regulated industryPhysical productsSells to businessesTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $44.00
- 52-Week Range
- $43.01 – $86.74
- Market Cap
- $7.24B
- P/E (TTM)
- —
- EPS (TTM)
- -3.48
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 16.40
- PEG Ratio
- 27.33
- Return on Equity
- -105.50%
- Return on Assets
- -12.43%
- Gross Margin
- -6.93%
- Operating Margin
- -38.18%
- Profit Margin
- -64.66%
- Current Ratio
- 7.89
- Debt/Equity
- 4.98
- Total Debt
- $2.19B
- Free Cash Flow
- $-346.76M
- Revenue Growth
- -40.70%
- Earnings Growth
- —
- Enterprise Value
- $7.32B
Market Snapshot
About
Ionis Pharmaceuticals is a biotechnology company pioneering RNA-targeted therapeutics. The company uses its proprietary antisense technology platform to design medicines that regulate RNA to treat diseases. Ionis has brought multiple drugs to market and has a robust pipeline targeting neurological diseases, cardiovascular conditions, and rare diseases. The company partners with major pharmaceutical firms and receives royalties from approved drugs including Spinraza for spinal muscular atrophy.